Researchers at the University of Kent have discovered that madecassic acid, a popular skin-soothing ingredient, effectively inhibits antibiotic-resistant bacteria by targeting a unique bacterial respiratory protein. The team has engineered modified variants of this compound to enhance its antimicrobial potency. This discovery offers a novel, dual-action solution for next-generation skin health products and potential pharmaceutical applications.
Madecassic acid is a natural compound widely recognized for its skin-soothing properties in cosmetic formulations. Research from the University of Kent has identified that this extract also possesses potent antibacterial capabilities, particularly against antibiotic-resistant strains of bacteria. By targeting specific respiratory proteins unique to bacteria, this technology offers a dual-action approach for personal care products, providing both skin-soothing benefits and enhanced microbial protection.
The mechanism of action involves the binding of madecassic acid to the bacterial cytochrome bd complex, an essential respiratory protein absent in humans and animals. Inhibiting this complex prevents bacteria from generating the energy required for growth and survival. The research group has successfully synthesized modified chemical variants of the compound, which have demonstrated robust antimicrobial efficacy. These variants allow for fine-tuned biological activity, enabling the development of targeted formulations that address both pathogenic threats and skin microbiota balance.
The technology is currently at TRL 4, as it has undergone successful laboratory validation, including computational screening, molecular docking, and testing against live bacterial models, with the results published in peer-reviewed literature. Further development is required to optimize these variants for commercial applications.
The University of Kent is a large, comprehensive public research university with an international outlook and a strong civic role in Kent and the South East. Its Canterbury and Medway campuses connect researchers with regional partners through the shared Universities at Medway setting and the Historic Dockyard Chatham. Proximity to Discovery Park and the Kent and Medway Medical School supports practical collaboration with life-science companies, clinicians, NHS providers and public-sector organisations. Research draws on competitive funding from UKRI and its councils, Innovate UK, NIHR and other public and charitable sponsors; commercialisation staff support IP, licensing, spin-outs, contract research and Knowledge Transfer Partnerships.